Enasidenib Nitroso Impurity 2
Synchemia is a leading Manufacturer in pharmaceutical Nitrosamine compounds.Enasidenib is used to treat acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation in patients who have not responded to other treatments or to those whose cancer has come back after treatment.Enasidenib Nitroso Impurity 2 is a highly toxic organic compound and a suspected human carcinogen. Handle the material carefully with proper safety measures.
Enasidenib Nitroso Impurity 2 CAS NO: NA chemically represented as N-(4-((2-Hydroxy-2-methylpropyl)(nitroso)amino)-6-(6-(trifluoromethyl)pyridin-2-yl)-1,3,5-triazin-2-yl)-N-(2-(trifluoromethyl)pyridin-4-yl)nitrous amide. Synchemia is the leading manufacturing and exporter of Enasidenib Nitroso Impurity 2 . We supply Enasidenib Nitroso Impurity 2 with detailed characterization data compliance with regulatory guidelines.
Make an Enquiry for Abacavir EP Impurity A
Related Products
| CAT No | SRC-N0143716 |
| CAS No | NA |
| Mol.F. | C25H22N8O6 |
| Mol.Wt. | 530.5 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143717 |
| CAS No | NA |
| Mol.F. | C27H29N9O5 |
| Mol.Wt. | 559.6 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143718 |
| CAS No | NA |
| Mol.F. | C27H31N9O3 |
| Mol.Wt. | 529.6 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143719 |
| CAS No | NA |
| Mol.F. | C26H27N9O5 |
| Mol.Wt. | 545.6g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143720 |
| CAS No | NA |
| Mol.F. | C26H29N9O3 |
| Mol.Wt. | 515.6 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143721 |
| CAS No | NA |
| Mol.F. | C30H33N9O4 |
| Mol.Wt. | 583.7 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143722 |
| CAS No | NA |
| Mol.F. | C29H31N9O4 |
| Mol.Wt. | 569.6 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143723 |
| CAS No | NA |
| Mol.F. | C16H19N3O7S |
| Mol.Wt. | 397.4 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143724 |
| CAS No | NA |
| Mol.F. | C15H19N3O5S |
| Mol.Wt. | 353.4 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143725 |
| CAS No | NA |
| Mol.F. | C32H37N5O5S |
| Mol.Wt. | 603.7 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143726 |
| CAS No | NA |
| Mol.F. | C48H55N7O9S2 |
| Mol.Wt. | 938.1 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143727 |
| CAS No | NA |
| Mol.F. | C16H19N3O6S |
| Mol.Wt. | 381.4g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143728 |
| CAS No | NA |
| Mol.F. | C16H18N215N2O2 |
| Mol.Wt. | 300.3 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143729 |
| CAS No | NA |
| Mol.F. | C32H37N5O5S |
| Mol.Wt. | 603.7 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143730 |
| CAS No | NA |
| Mol.F. | C16H19N215NO |
| Mol.Wt. | 270.3 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |
| CAT No | SRC-N0143731 |
| CAS No | NA |
| Mol.F. | C11H12D4N2O3 |
| Mol.Wt. | 228.3 g/mole |
| INV STATUS | CUSTOM SYNTHESIS |